Brokerages Anticipate Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.35 Per Share
Wall Street analysts expect Endocyte, Inc. (NASDAQ:ECYT) to post earnings of ($0.35) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Endocyte’s earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.19). Endocyte posted earnings of ($0.21) per share in the same quarter last year, which suggests a negative year over year growth rate of 66.7%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that Endocyte will report full year earnings of ($1.06) per share for the current year, with EPS estimates ranging from ($1.22) to ($0.89). For the next financial year, analysts expect that the business will report earnings of ($0.85) per share, with EPS estimates ranging from ($0.89) to ($0.80). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Endocyte.
Endocyte (NASDAQ:ECYT) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. The firm had revenue of $0.01 million for the quarter. During the same period in the prior year, the firm earned ($0.25) earnings per share.
A number of equities research analysts recently issued reports on the company. Cowen and Company reissued a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd. Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, October 3rd. ValuEngine raised Endocyte from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Endocyte currently has a consensus rating of “Hold” and a consensus price target of $7.00.
Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in Endocyte by 1,064.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after purchasing an additional 393,975 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Endocyte by 34.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 25,003 shares in the last quarter. FMR LLC raised its position in Endocyte by 0.9% during the 2nd quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after purchasing an additional 31,168 shares in the last quarter. LMR Partners LLP bought a new stake in Endocyte during the 2nd quarter valued at $196,000. Finally, Spark Investment Management LLC bought a new stake in Endocyte during the 2nd quarter valued at $177,000. 25.64% of the stock is owned by hedge funds and other institutional investors.
Endocyte (NASDAQ:ECYT) opened at 4.535 on Wednesday. The firm’s market cap is $193.08 million. The firm’s 50 day moving average price is $3.08 and its 200-day moving average price is $2.14. Endocyte has a one year low of $1.17 and a one year high of $6.55.
Endocyte Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.